Gene knockdown is a common method for studying gene function by reducing messenger ribonucleic acid (mRNA) levels without altering the deoxyribonucleic acid (DNA). Among the available techniques, RNA ...

Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license option ...

Founded in 1992, Sirna Therapeutics was one of the earliest biotechnology companies focused on developing therapeutics based on RNA interference (RNAi), specifically using small interfering RNA (siRNA ...

Two start-ups have launched to develop next-generation drugs using small interfering RNA (siRNA) to silence genes. The first, Judo Bio, is a spin-off of the venture capital firm Atlas Venture. The ...

This is an introduction to the biological mechanism of RNA interference (RNAi) and experimental application of short, interfering RNA (siRNA). The key steps of the endogenous RNAi pathway will be ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small interfering RNA (siRNA) candidates in epilepsy and Huntington’s disease. The ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship manufacturing facility in Massachusetts. Alnylam plans to spend $250 million in a ...